No black box warning on record for Koselugo

As of the latest FDA labeling reviewed, Koselugo (SELUMETINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Koselugo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Left Ventricular Dysfunction : Assess ejection fraction prior to initiating treatment, every 3 months during the first year, then every 6 months thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue KOSELUGO based on severity of adverse reaction. ( 2.3 , 5.1 ) • Ocular Toxicity : Conduct ophthalmic assessments prior to initiating

No black box warning on record for Koselugo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Left Ventricular Dysfunction : Assess ejection fraction prior to initiating treatment, every 3 months during the first year, then every 6 months thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue KOSELUGO based on severity of adverse reaction. ( 2.3 , 5.1 ) • Ocular Toxicity : Conduct ophthalmic assessments prior to initiating

Koselugo Black Box Warning

No black box warning on record for Koselugo

Other warnings & precautions

Koselugo Black Box Warning

No black box warning on record for Koselugo

Other warnings & precautions